title: Is there a role for endothelin antagonists in diabetic renal disease?
authors.affiliation: Department of Medicine, University of Melbourne, Heidelberg West, Australia.
authors.forename: K
authors.initials: K
authors.lastname: Jandeleit-Dahm
authors.forename: T J
authors.initials: TJ
authors.lastname: Allen
authors.forename: S
authors.initials: S
authors.lastname: Youssef
authors.forename: R E
authors.initials: RE
authors.lastname: Gilbert
authors.forename: M E
authors.initials: ME
authors.lastname: Cooper
mesh_terms: D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000378:metabolism; D048909:Diabetes Complications; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000503:physiopathology*; D004195:Disease Models, Animal; D065128:Endothelin Receptor Antagonists; D000072396:Endothelin-Converting Enzymes; D016232:Endothelins / Q000502:physiology*; D006801:Humans; D006977:Hypertension, Renal / Q000209:etiology / Q000503:physiopathology; D008666:Metalloendopeptidases; D051381:Rats
chemical_list: D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes